Validation of an AI-enabled exome/transcriptome liquid biopsy platform for early detection, MRD, disease monitoring, and therapy selection for solid tumors

Validation of an AI-enabled exome/transcriptome liquid biopsy platform for early detection, MRD, disease monitoring, and therapy selection for solid tumors

Abstract Effective clinical management of patients with cancer requires highly accurate diagnosis, precise therapy selection, and highly sensitive monitoring of disease burden. Caris Assure is a multifunctional blood-based assay that couples whole exome and whole transcriptome sequencing on plasma a...

Full description

Saved in:
Bibliographic Details
Main Authors: J. Abraham, V. Domenyuk, N. Perdigones, S. Klimov, S. Antani, T. Yoshino, E. I. Heath, E. Lou, S. V. Liu, J. L. Marshall, W. S. El-Deiry, A. F. Shields, M. F. Dietrich, Y. Nakamura, T. Fujisawa, G. D. Demetri, A. Barker, J. Xiu, D. A. Sacchetti, S. Stahl, R. Hahn-Lowry, A. Stark, J. Swensen, G. Poste, D. D. Halbert, M. Oberley, M. Radovich, G. W. Sledge, David B. Spetzler
Format: Article
Language:English
Published: Nature Portfolio 2025-07-01
Series:Scientific Reports
Subjects:
MCED
Liquid biopsy
Whole exome
Whole transcriptome
MRD
AI
Online Access:https://doi.org/10.1038/s41598-025-08986-0
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41598-025-08986-0

Similar Items